Eli Lilly today announced plans to open a new Lilly Gateway Labs (LGL) site in Philadelphia.
The new Gateway Labs site will occupy 44,000 square feet of 2300 Market, a life sciences facility in Center City. Biotechs based in the site will have access to dedicated, fully equipped wet lab facilities alongside strategic scientific engagement.
With the addition of Philadelphia, Gateway's U.S. footprint now includes four geographic centers of innovation, including Boston, South San Francisco, and San Diego. In each locale, Lilly Gateway Labs serves as a catalyst for community-building across life science sectors, synergizing the efforts of biotechs, venture partners, and other ecosystem partners.
Lilly Gateway Labs is part of Lilly Catalyze360, alongside Lilly Ventures, Lilly ExploR&D, and Lilly TuneLab, which together support biotech innovation by providing access to strategic capital, lab space and technology, and research and development capabilities including advanced AI models. Since the first Gateway Labs site opened in 2019, resident companies have collectively raised more than $3 billion, fueling progress on over 50 therapeutic programs.
